Despite concerns, a new study has shown that CBD is not associated with liver abnormalities in healthy volunteers.
The study published in the Journal of Cannabis and Cannabinoid Research revealed that oral CBD is not associated with liver abnormality. This includes the elevated production of certain liver enzymes.
Previous studies on CBD and the liver have reported conflicting results. One fear is that it may impact the body’s ability to absorb medications.
CBD and liver research
Researchers conducted the study on a group of 1,500 volunteers over thirty days. The observational research then recorded all the data through an app platform. This included demographic information, medical history, reasons for taking, dosage, adverse effects and efficacy. Patients were recruited through different CBD companies and were already familiar with the products.
A selection of different products was used, including full-spectrum (55.7 percent), CBD isolate (40.5 percent), and broad-spectrum (3.8 percent).
After 30 days, patients with elevated alanine transaminase (ALT) values were given a follow-up appointment. ALT is an enzyme found in the liver that converts protein into energy. High levels of ALT may mean damage from hepatitis, infection, cancer or other conditions.
Liver results
Lab testing showed no association between the CBD products and liver abnormalities.
Regarding the alleviated ALT levels in 33 patients, 21 were reported as normal in further liver tests, while eight remained the same. There were four cases of increased ALT, of which one returned to normal levels.
Disclaimer: https://cannabishealthnews.co.uk/2022/01/05/study-shows-cbd-not-associated-with-liver-abnormalities
